pharma news today obesity drugs glp-1 october 2025 Drugs: Pulse Survey (U.S.) ADA '26: Lilly's dominance, Pfizer's

While not yet tested in large human trials, these findings suggest Dihexa may have future therapeutic roles in: Some studies point to Dihexas ability to activate the c-Met receptor , a pathway involved in tissue repair, angiogenesis (formation of new blood vessels), and inflammation modulation

Both peptides stimulate your pituitary gland to release more growth hormone

Despite reducing inflammation, non-steroidal anti-inflammatory drugs (NSAIDs) can disrupt oxidative phosphorylation and decrease the intracellular concentrations of adenosine triphosphate (ATP) (Somasundaram et al

doi: 10.1007/BF02980677 46 GuoX.MeiN

New aspects of the blood-brain barrier transporters